1
|
Alonso C, Martí M, Ramos A, Calpena AC, Clares-Naveros B, Coderch L. A Synthetic Model of the Mucosa for Oral Penetration Studies. MEMBRANES 2023; 13:905. [PMID: 38132909 PMCID: PMC10745054 DOI: 10.3390/membranes13120905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 12/04/2023] [Accepted: 12/10/2023] [Indexed: 12/23/2023]
Abstract
The main objective of this study is the evaluation of the use of a synthetic membrane, Nuclepore, as a model for permeation studies through sublingual mucosa. The permeability of two types of membranes, porcine sublingual oral mucosa and a synthetic Nuclepore membrane, to water was compared. Moreover, the water permeability of membranes modified with waterproofing formulations was measured to study their ability to protect against the penetration of viruses, toxins, etc. A relatively high correlation (R2 0.88) was obtained between the transmucosal water loss (TMWL) values of the artificial membrane and the mucosa. These results support the possible use of this synthetic membrane in the screening of the water permeability of formulations. In addition, studies of the permeation of different actives, drugs, and biocides through the two membranes were carried out, and these results were compared with their skin permeation data. The synthetic membrane does not seem to discern between compounds in terms of permeability. However, the permeation of caffeine through intact or modified membranes incorporating waterproofing formulations presents similar permeation profiles through the synthetic membrane and mucosa. The results from these assays should lend support to the use of this synthetic membrane when screening formulations to be applied in oral penetration studies.
Collapse
Affiliation(s)
- Cristina Alonso
- Surfactants and Nanobiotechnology Department, Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona 18-26, 08034 Barcelona, Spain; (C.A.); (M.M.); (A.R.)
| | - Meritxell Martí
- Surfactants and Nanobiotechnology Department, Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona 18-26, 08034 Barcelona, Spain; (C.A.); (M.M.); (A.R.)
| | - Anderson Ramos
- Surfactants and Nanobiotechnology Department, Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona 18-26, 08034 Barcelona, Spain; (C.A.); (M.M.); (A.R.)
| | - Ana Cristina Calpena
- Department of Pharmacy and Pharmaceutical Technology, Universitat de Barcelona, Avda. Joan XXIII s/n, 08028 Barcelona, Spain;
| | - Beatriz Clares-Naveros
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain;
- Biosanitary Research Institute of Granada (ibs. GRANADA), Avda de Madrid 15, 18012 Granada, Spain
| | - Luisa Coderch
- Surfactants and Nanobiotechnology Department, Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona 18-26, 08034 Barcelona, Spain; (C.A.); (M.M.); (A.R.)
| |
Collapse
|
2
|
Hashemi P, Mahmoodi S, Ghasemian A. An updated review on oral protein-based antigen vaccines efficiency and delivery approaches: a special attention to infectious diseases. Arch Microbiol 2023; 205:289. [PMID: 37468763 DOI: 10.1007/s00203-023-03629-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2023] [Revised: 07/04/2023] [Accepted: 07/09/2023] [Indexed: 07/21/2023]
Abstract
Various infectious agents affect human health via the oral entrance. The majority of pathogens lack approved vaccines. Oral vaccination is a convenient, safe and cost-effective approach with the potential of provoking mucosal and systemic immunity and maintaining individual satisfaction. However, vaccines should overcome the intricate environment of the gastrointestinal tract (GIT). Oral protein-based antigen vaccines (OPAVs) are easier to administer than injectable vaccines and do not require trained healthcare professionals. Additionally, the risk of needle-related injuries, pain, and discomfort is eliminated. However, OPAVs stability at environmental and GIT conditions should be considered to enhance their stability and facilitate their transport and storage. These vaccines elicit the local immunity, protecting GIT, genital tract and respiratory epithelial surfaces, where numerous pathogens penetrate the body. OPAVs can also be manipulated (such as using specific incorporated ligand and receptors) to elicit targeted immune response. However, low bioavailability of OPAVs necessitates development of proper protein carriers and formulations to enhance their stability and efficacy. There are several strategies to improve their efficacy or protective effects, such as incorporation of adjuvants, enzyme inhibitors, mucoadhesive or penetrating devices and permeation enhancers. Hence, efficient delivery of OPAVs into GIT require proper delivery systems mainly including smart target systems, probiotics, muco-adhesive carriers, lipid- and plant-based delivery systems and nano- and microparticles.
Collapse
Affiliation(s)
- Parisa Hashemi
- Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
| | - Shirin Mahmoodi
- Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
| | - Abdolmajid Ghasemian
- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
| |
Collapse
|
3
|
Peter CM, da Silva Barcelos L, Ferreira MRA, Waller SB, Frühauf MI, Botton NY, Conceição FR, de Lima M, de Oliveira Hübner S, Barichello JM, Fischer G. Immunogenicity of an inactivated vaccine for intravaginal application against bovine alphaherpesvirus type 5 (BoHV-5). Mol Immunol 2023; 155:69-78. [PMID: 36731192 DOI: 10.1016/j.molimm.2023.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 01/17/2023] [Accepted: 01/18/2023] [Indexed: 02/04/2023]
Abstract
The present study was carried out to evaluate the intravaginal vaccine potential against bovine alphaherpesvirus type 5 (BoHV-5). Sixty three cows were divided into seven groups (n: 9) and inoculated intravaginally (VA) or intramuscularly (IM) with inactivated BoHV-5, associated with the recombinant B subunit of the heat-labile enterotoxin of E. coli (rLTB), 2-hydroxyethylcellulose (Drug Delivery System A - DDS-A) or Poloxamer 407 (Drug Delivery System B - DDS-B) as follows: G1 (DDS-A + BoHV-5 + rLTB), G2 (DDS-A + BoHV-5), G3 (DDS-B + BoHV-5 + rLTB), G4 (DDS-B + BoHV-5), G5 (BoHV-5 + rLTB), G6 (Negative control) e G7 (Positive control). The local and systemic humoral responses were measured by indirect ELISA (IgA and IgG) and serum neutralization tests, and the cellular response was measured by a quantitative direct ELISA (IL-2 and IFN-Gamma). The results showed the group inoculated by the IM route, G5, demonstrated the highest levels of IgG in the vaginal mucosa among the experimental groups (p < 0.05). In the groups tested with polymers (G1 and G3) in the vaginal mucosa, even higher levels of IgG were seen in comparison to the positive control (G7; p < 0.01). Higher levels of IgA were also noted in relation to the other groups (p < 0.05) on days 30, 60 and 90 post-inoculations. The groups G1 and G3 also provided higher titers of neutralizing antibodies (Log2) in relation to other treatments (p < 0.01) 90 days after inoculation. In the nasal mucosa, there was an increase in the levels of IgA and IgG with the use of vaccines from groups G1 and G3, in relation to the positive control, G7 (p < 0.05) at 60 and 90 days after the first inoculation. Moreover, neutralizing antibodies titers were detected at 60 and 90 days by serum neutralization. The inclusion of the evaluated polymers resulted in a superior response (p < 0.05) of immunoglobulins and IL-2 and IFN-Gamma in relation to the treatment using only rLTB (G5). This data demonstrates the capabilities of a vaccine with an intravaginal application in cattle to stimulate a local and systemic immune response.
Collapse
Affiliation(s)
- Cristina Mendes Peter
- Laboratory of Virology and Immunology, Veterinary College, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Lariane da Silva Barcelos
- Laboratory of Virology and Immunology, Veterinary College, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Marcos Roberto Alves Ferreira
- Applied Immunology Laboratory. Technological Development Center, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Stefanie Bressan Waller
- Applied Immunology Laboratory. Technological Development Center, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Matheus Iuri Frühauf
- Laboratory of Virology and Immunology, Veterinary College, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Nadálin Yandra Botton
- Laboratory of Virology and Immunology, Veterinary College, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Fabricio Rochedo Conceição
- Applied Immunology Laboratory. Technological Development Center, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Marcelo de Lima
- Laboratory of Virology and Immunology, Veterinary College, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Silvia de Oliveira Hübner
- Laboratory of Virology and Immunology, Veterinary College, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - José Mario Barichello
- Pharmaceutical Development and Production Laboratory, Center for Pharmaceutical and Food Chemical Sciences, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Geferson Fischer
- Laboratory of Virology and Immunology, Veterinary College, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil.
| |
Collapse
|
4
|
Tiwari N, Osorio‐Blanco ER, Sonzogni A, Esporrín‐Ubieto D, Wang H, Calderón M. Nanocarriers for Skin Applications: Where Do We Stand? Angew Chem Int Ed Engl 2022. [DOI: 10.1002/ange.202107960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Neha Tiwari
- POLYMAT Applied Chemistry Department Faculty of Chemistry University of the Basque Country UPV/EHU Paseo Manuel de Lardizabal 3 20018 Donostia-San Sebastián Spain
| | - Ernesto Rafael Osorio‐Blanco
- POLYMAT Applied Chemistry Department Faculty of Chemistry University of the Basque Country UPV/EHU Paseo Manuel de Lardizabal 3 20018 Donostia-San Sebastián Spain
| | - Ana Sonzogni
- Group of Polymers and Polymerization Reactors INTEC (Universidad Nacional del Litoral-CONICET) Güemes 3450 Santa Fe 3000 Argentina
| | - David Esporrín‐Ubieto
- POLYMAT Applied Chemistry Department Faculty of Chemistry University of the Basque Country UPV/EHU Paseo Manuel de Lardizabal 3 20018 Donostia-San Sebastián Spain
| | - Huiyi Wang
- POLYMAT Applied Chemistry Department Faculty of Chemistry University of the Basque Country UPV/EHU Paseo Manuel de Lardizabal 3 20018 Donostia-San Sebastián Spain
| | - Marcelo Calderón
- POLYMAT Applied Chemistry Department Faculty of Chemistry University of the Basque Country UPV/EHU Paseo Manuel de Lardizabal 3 20018 Donostia-San Sebastián Spain
- IKERBASQUE, Basque Foundation for Science 48009 Bilbao Spain
| |
Collapse
|
5
|
Tiwari N, Osorio‐Blanco ER, Sonzogni A, Esporrín‐Ubieto D, Wang H, Calderón M. Nanocarriers for Skin Applications: Where Do We Stand? Angew Chem Int Ed Engl 2022; 61:e202107960. [PMID: 34487599 PMCID: PMC9292798 DOI: 10.1002/anie.202107960] [Citation(s) in RCA: 49] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Indexed: 12/15/2022]
Abstract
Skin penetration of active molecules for treatment of diverse diseases is a major field of research owing to the advantages associated with the skin like easy accessibility, reduced systemic-derived side effects, and increased therapeutic efficacy. Despite these advantages, dermal drug delivery is generally challenging due to the low skin permeability of therapeutics. Although various methods have been developed to improve skin penetration and permeation of therapeutics, they are usually aggressive and could lead to irreversible damage to the stratum corneum. Nanosized carrier systems represent an alternative approach for current technologies, with minimal damage to the natural barrier function of skin. In this Review, the use of nanoparticles to deliver drug molecules, genetic material, and vaccines into the skin is discussed. In addition, nanotoxicology studies and the recent clinical development of nanoparticles are highlighted to shed light on their potential to undergo market translation.
Collapse
Affiliation(s)
- Neha Tiwari
- POLYMATApplied Chemistry DepartmentFaculty of ChemistryUniversity of the Basque CountryUPV/EHUPaseo Manuel de Lardizabal 320018Donostia-San SebastiánSpain
| | - Ernesto Rafael Osorio‐Blanco
- POLYMATApplied Chemistry DepartmentFaculty of ChemistryUniversity of the Basque CountryUPV/EHUPaseo Manuel de Lardizabal 320018Donostia-San SebastiánSpain
| | - Ana Sonzogni
- Group of Polymers and Polymerization ReactorsINTEC (Universidad Nacional del Litoral-CONICET)Güemes 3450Santa Fe3000Argentina
| | - David Esporrín‐Ubieto
- POLYMATApplied Chemistry DepartmentFaculty of ChemistryUniversity of the Basque CountryUPV/EHUPaseo Manuel de Lardizabal 320018Donostia-San SebastiánSpain
| | - Huiyi Wang
- POLYMATApplied Chemistry DepartmentFaculty of ChemistryUniversity of the Basque CountryUPV/EHUPaseo Manuel de Lardizabal 320018Donostia-San SebastiánSpain
| | - Marcelo Calderón
- POLYMATApplied Chemistry DepartmentFaculty of ChemistryUniversity of the Basque CountryUPV/EHUPaseo Manuel de Lardizabal 320018Donostia-San SebastiánSpain
- IKERBASQUE, Basque Foundation for Science48009BilbaoSpain
| |
Collapse
|
6
|
Kalam MA, Alkholief M, Badran M, Alshememry A, Alshamsan A. Co-encapsulation of metformin hydrochloride and reserpine into flexible liposomes: Characterization and comparison of in vitro release profile. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.101670] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Diogo GR, Hart P, Copland A, Kim MY, Tran AC, Poerio N, Singh M, Paul MJ, Fraziano M, Reljic R. Immunization With Mycobacterium tuberculosis Antigens Encapsulated in Phosphatidylserine Liposomes Improves Protection Afforded by BCG. Front Immunol 2019; 10:1349. [PMID: 31293568 PMCID: PMC6598733 DOI: 10.3389/fimmu.2019.01349] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Accepted: 05/28/2019] [Indexed: 11/13/2022] Open
Abstract
Liposomes have been long considered as a vaccine delivery system but this technology remains to be fully utilized. Here, we describe a novel liposome-based subunit vaccine formulation for tuberculosis (TB) based on phosphatidylserine encapsulating two prominent TB antigens, Ag85B, and ESAT-6. We show that the resulting liposomes (Lipo-AE) are stable upon storage and can be readily taken up by antigen presenting cells and that their antigenic cargo is delivered and processed within endosomal cell compartments. The Lipo-AE vaccine formulation combined with the PolyIC adjuvant induced a mixed Th1/Th17-Th2 immune response to Ag85B but only a weak response to ESAT-6. An immunization regimen based on systemic delivery followed by mucosal boost with Lipo-AE resulted in the accumulation of resident memory T cells in the lungs. Most importantly though, when Lipo-AE vaccine candidate was administered to BCG-immunized mice subsequently challenged with low dose aerosol Mycobacterium tuberculosis, we observed a significant reduction of the bacterial load in the lungs and spleen compared to BCG alone. We therefore conclude that the immunization with mycobacterial antigens delivered by phosphatidylserine based liposomes in combination with Poly:IC adjuvant may represent a novel BCG boosting vaccination strategy.
Collapse
Affiliation(s)
- Gil R Diogo
- Institute for Infection and Immunity, St. George's University of London, London, United Kingdom
| | - Peter Hart
- Institute for Infection and Immunity, St. George's University of London, London, United Kingdom
| | - Alastair Copland
- Institute for Infection and Immunity, St. George's University of London, London, United Kingdom
| | - Mi-Young Kim
- Institute for Infection and Immunity, St. George's University of London, London, United Kingdom
| | - Andy C Tran
- Institute for Infection and Immunity, St. George's University of London, London, United Kingdom
| | - Noemi Poerio
- Dipartimento di Biologia, University of Rome Tor Vergata, Rome, Italy
| | | | - Matthew J Paul
- Institute for Infection and Immunity, St. George's University of London, London, United Kingdom
| | - Maurizio Fraziano
- Dipartimento di Biologia, University of Rome Tor Vergata, Rome, Italy
| | - Rajko Reljic
- Institute for Infection and Immunity, St. George's University of London, London, United Kingdom
| |
Collapse
|
8
|
Jia Y, McCluskie MJ, Zhang D, Monette R, Iqbal U, Moreno M, Sauvageau J, Williams D, Deschatelets L, Jakubek ZJ, Krishnan L. In vitro evaluation of archaeosome vehicles for transdermal vaccine delivery. J Liposome Res 2017; 28:305-314. [DOI: 10.1080/08982104.2017.1376683] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Yimei Jia
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| | - Michael J. McCluskie
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| | - Dongling Zhang
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| | - Robert Monette
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| | - Umar Iqbal
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| | - Maria Moreno
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| | - Janelle Sauvageau
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| | - Dean Williams
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| | - Lise Deschatelets
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| | - Zygmunt J. Jakubek
- Department of Measurement Science and Standards, National Research Council Canada, Ottawa, Canada
| | - Lakshmi Krishnan
- Department of Human Health Therapeutics, National Research Council Canada, Ottawa, Canada
| |
Collapse
|
9
|
Zhao G, Chandrudu S, Skwarczynski M, Toth I. The application of self-assembled nanostructures in peptide-based subunit vaccine development. Eur Polym J 2017; 93:670-681. [PMID: 32226094 PMCID: PMC7094324 DOI: 10.1016/j.eurpolymj.2017.02.014] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Revised: 01/19/2017] [Accepted: 02/08/2017] [Indexed: 02/06/2023]
Abstract
Smaller polymer-peptide conjugates-based nanoparticles are often more immunogenic. Lipid-antigen conjugates-based nanoparticles can interact with immune receptors. Peptides with β-sheet conformation usually form nanofibers. α-Helical and random coil peptides tend to self-assemble into nanoparticles. Peptide-based nanostructures are usually poorer inducers of immune responses.
Peptide based-vaccines are becoming one of the most widely investigated prophylactic and therapeutic health care interventions against a variety of diseases, including cancer. However, the lack of a safe and highly efficient adjuvant (immune stimulant) is regarded as the biggest obstacle to vaccine development. The incorporation of a peptide antigen in a nanostructure-based delivery system was recently shown to overcome this obstacle. Nanostructures are often formed from antigens conjugated to molecules such as polymers, lipids, and peptide, with the help of self-assembly phenomenon. This review describes the application of self-assembly process for the production of peptide-based vaccine candidates and the ability of these nanostructures to stimulate humoral and cellular immune responses.
Collapse
Key Words
- (C18)2, N,N-dioctadecyl succinamic acid
- APC, antigen-presenting cell
- BMA, butyl methacrylate
- C16, 2-(R/S)-hexadecanoic acid
- CFA, complete Freund's adjuvant
- Conjugation
- CuAAC, copper-catalyzed azide-alkyne cycloaddition
- DLS, dynamic light scattering
- ELISA, enzyme-linked immunosorbent assay
- FDA, Food and Drug Administration
- GAS, group A streptococcus
- HCV, hepatitis C virus
- HIV, human immunodeficiency virus
- HPV, human papilloma virus
- IFA, incomplete Freund’s adjuvant
- IgG, immunoglobulin G
- LCP, lipid core peptide
- Lipopeptide
- Nanofiber
- Nanoparticle
- OVA, ovalbumin
- PADRE, pan DR epitope
- PBS, phosphate-buffered saline
- PDSMA, pyridyl disulfide methacrylamide
- PEG-PPS, poly(ethylene glycol)-stabilized poly(propylene sulfide) core nanoparticle
- Pam2Cys, dipalmitoyl-S-glyceryl cysteine
- Pam3Cys, tripalmitoyl-S-glyceryl cysteine
- PbCSP, Plasmodium berghei circumsporozoite protein
- Polymer
- SAP, self-assembling polypeptide
- SARS, severe acute respiratory syndrome
- Self-assembly
- T-VEC, talimogene laherparepvec
- TEM, transmission electron microscopy
- TLR2, toll-like receptor 2
- TLR4, toll-like receptor 4
- TLR9, toll-like receptor 9
- VLP, virus-like particle
- Vaccine
Collapse
Affiliation(s)
- Guangzu Zhao
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, Queensland 4072, Australia
| | - Saranya Chandrudu
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, Queensland 4072, Australia
| | - Mariusz Skwarczynski
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, Queensland 4072, Australia
| | - Istvan Toth
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, Queensland 4072, Australia
- Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, Queensland 4072, Australia
- Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Brisbane, Queensland 4102, Australia
- Corresponding author at: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.
| |
Collapse
|
10
|
Shimizu Y, Iwasaki T, Tajima T, Yuba E, Kono K, Watarai S. Induction of antibody response in the oral cavity of dogs following intraocular (eye drop) immunization with Porphyromonas gingivalis cell lysate incorporated in pH-sensitive fusogenic polymer-modified liposomes. J Vet Med Sci 2016; 79:290-298. [PMID: 27916762 PMCID: PMC5326933 DOI: 10.1292/jvms.16-0338] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Induction of mucosal immune responses against Porphyromonas gingivalis within the oral cavity of dogs was studied by immunizing with pH-sensitive fusogenic polymer (MGluPG)-modified liposome-associated cell lysate. Dogs immunized with P. gingivalis cell lysate-containing MGluPG-modified liposomes by intraocular (eye drop) route displayed significant levels of P. gingivalis cell lysate-specific serum IgG and IgA as well as mucosal IgA antibodies in saliva secretion. Serum and salivary antibodies generated by intraocularly immunized with MGluPG-modified liposome-associated P. gingivalis cell lysate revealed a significant aggregation activity against P. gingivalis, whereas serum and saliva from dogs receiving MGluPG-modified liposomes unentrapping P. gingivalis cell lysate did not show the aggregation activity against P. gingivalis. Furthermore, P. gingivalis-specific antibodies in saliva of immunized dogs inhibited the adherence of P. gingivalis to cultured HeLa cells. More importantly, salivary antibodies induced by intraocular immunization with P. gingivalis cell lysate-containing MGluPG-modified liposomes significantly inhibited the coaggregation of P. gingivalis with Actinomyces naeslundii and the cell damage activity of P. gingivalis against FaDu cells, an oral epithelial cell. These results suggest that intraocularly administered P. gingivalis cell lysate-containing MGluPG-modified liposomes should be an effective mucosal vaccine against P. gingivalis infection in dogs and may be an important tool for the prevention of periodontitis.
Collapse
Affiliation(s)
- Yosuke Shimizu
- Division of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Izumisano, Osaka 598-8531, Japan
| | | | | | | | | | | |
Collapse
|
11
|
Vaz GC, Sharma NM, Zheng H, Zimmerman MC, Santos RS, Frezard F, Fontes MAP, Patel KP. Liposome-entrapped GABA modulates the expression of nNOS in NG108-15 cells. J Neurosci Methods 2016; 273:55-63. [PMID: 27523033 DOI: 10.1016/j.jneumeth.2016.08.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Revised: 07/25/2016] [Accepted: 08/05/2016] [Indexed: 01/08/2023]
Abstract
BACKGROUND Liposomes are concentric lipid vesicles that allow a sustained release of entrapped substances. GABA (γ-aminobutyric acid) is the most prevalent inhibitory neurotransmitter in the central nervous system. NEW METHOD Using GABA-containing liposomes (GL) prepared by the freeze-thawing method, we determined the effect of sustained release of GABA on expression of neuronal nitric oxide synthase (nNOS) and GABAA receptor (GABAAR) in an in vitro neuronal model. RESULTS Neuronal cell line NG108-15 treated with different doses of GL during 24h showed an increase in expression of GABAAR (54 and 50% with 10 and 20ng doses, respectively) and nNOS (138, 157 and 165% with 20, 50 and 100ng doses, respectively) compared with cells treated with empty liposomes (EL). Additionally, cells treated with 50ng of GL showed an increase in GABAAR (23%) after 1h followed by an increase in nNOS (55, 46 and 55%) at 8, 12 and 24h time points, respectively. Immunofluorescence experiments confirmed an increase in nNOS (134%) and basal intracellular levels of nitric oxide (84%) after GL treatment. Further, treatment of cells with GL showed a decrease in expression of a protein inhibitor of nNOS (PIN) (26, 66 and 57% with 20, 50 and 100ng doses respectively) compared with control. COMPARISON WITH EXISTING METHODS This is first demonstration for the development of GL that allows sustained slow release of this neurotransmitter. CONCLUSION These results suggest that a slow release of GABA can change the expression of nNOS possibly via alteration in PIN levels in neuronal cells.
Collapse
Affiliation(s)
- Gisele C Vaz
- Department of Physiology & Biophysics, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - Neeru M Sharma
- Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198-5850, United States
| | - Hong Zheng
- Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198-5850, United States
| | - Matthew C Zimmerman
- Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198-5850, United States
| | - Robson S Santos
- Department of Physiology & Biophysics, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - Frederic Frezard
- Department of Physiology & Biophysics, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - Marco A P Fontes
- Department of Physiology & Biophysics, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - Kaushik P Patel
- Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198-5850, United States.
| |
Collapse
|
12
|
Jiang PL, Lin HJ, Wang HW, Tsai WY, Lin SF, Chien MY, Liang PH, Huang YY, Liu DZ. Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity. Acta Biomater 2015; 11:356-67. [PMID: 25242652 DOI: 10.1016/j.actbio.2014.09.019] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 09/02/2014] [Accepted: 09/12/2014] [Indexed: 01/08/2023]
Abstract
Mucosal surfaces contain specialized dendritic cells (DCs) that are able to recognize foreign pathogens and mount protective immunity. We previously demonstrated that intranasal administration of targeted galactosylated liposomes can elicit mucosal and systemic antibody responses. In the present study, we assessed whether galactosylated liposomes could act as an effective DC-targeted mucosal vaccine that would be capable of inducing systemic anti-tumor immunity as well as antibody responses. We show that targeted galactosylated liposomes effectively facilitated antigen uptake by DCs beyond that mediated by unmodified liposomes both in vitro and in vivo. Targeted galactosylated liposomes induced higher levels of pro-inflammatory cytokines than unmodified liposomes in vitro. C57BL/6 mice thrice immunized intranasally with ovalbumin (OVA)-encapsulated galactosylated liposomes produced high levels of OVA-specific IgG antibodies in their serum. Spleen cells from mice receiving galactosylated liposomes were restimulated with OVA and showed significantly augmented levels of IFN-γ, IL-4, IL-5 and IL-6. In addition, intranasal administration of OVA-encapsulated beta-galactosylated liposomes resulted in complete protection against EG7 tumor challenge in C57BL/6 mice. Taken together, these results indicate that nasal administration of a galactosylated liposome vaccine mediates the development of an effective immunity against tumors and might be useful for further clinical anti-tumoral applications.
Collapse
|
13
|
Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2014; 10:431-40. [DOI: 10.1016/j.nano.2013.08.012] [Citation(s) in RCA: 73] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2013] [Revised: 07/31/2013] [Accepted: 08/26/2013] [Indexed: 01/19/2023]
|
14
|
Recent Developments in Preclinical DNA Vaccination. Vaccines (Basel) 2014; 2:89-106. [PMID: 26344468 PMCID: PMC4494203 DOI: 10.3390/vaccines2010089] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2013] [Revised: 11/22/2013] [Accepted: 11/26/2013] [Indexed: 12/21/2022] Open
Abstract
The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here.
Collapse
|
15
|
Gebril A, Alsaadi M, Acevedo R, Mullen AB, Ferro VA. Optimizing efficacy of mucosal vaccines. Expert Rev Vaccines 2014; 11:1139-55. [DOI: 10.1586/erv.12.81] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
16
|
Gebril AM, Lamprou DA, Alsaadi MM, Stimson WH, Mullen AB, Ferro VA. Assessment of the antigen-specific antibody response induced by mucosal administration of a GnRH conjugate entrapped in lipid nanoparticles. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2013; 10:971-9. [PMID: 24374362 DOI: 10.1016/j.nano.2013.12.005] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/27/2012] [Revised: 11/28/2013] [Accepted: 12/18/2013] [Indexed: 01/14/2023]
Abstract
UNLABELLED Vaccines administered parenterally have been developed against gonadotrophin-releasing hormone (GnRH) for anti-fertility and anti-cancer purposes. The aim of this study was to demonstrate whether mucosal delivery using GnRH immunogens entrapped in lipid nanoparticles (LNP) could induce anti-GnRH antibody titers. Immunogens consisting of KLH (keyhole limpet hemocyanin) conjugated to either GnRH-I or GnRH-III analogues were entrapped in LNP. Loaded non-ionic surfactant vesicles (NISVs) were administered subcutaneously, while nasal delivery was achieved using NISV in xanthan gum and oral delivery using NISV containing deoxycholate (bilosomes). NISV and bilosomes had similar properties: they were spherical, in the nanometre size range, with a slightly negative zeta potential and surface properties that changed with protein loading and inclusion of xanthan gum. Following immunization in female BALB/c mice, systemic antibody responses were similar for both GnRH-I and GnRH-III immunization. Only nasal delivery proved to be successful in terms of producing systemic and mucosal antibodies. FROM THE CLINICAL EDITOR The main research question addressed in this study was whether mucosal delivery using gonadotrophin-releasing hormone immunogens entrapped in lipid nanoparticles could induce anti-GnRH antibody titers. Only nasal delivery proved to be successful in terms of producing systemic and mucosal antibodies with this approach.
Collapse
Affiliation(s)
- Ayman M Gebril
- Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK; Faculty of Veterinary Medicine, Omar Al-Mukhtar University, Al-Bayda, Libya
| | - Dimitrios A Lamprou
- Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK
| | - Manal M Alsaadi
- Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK
| | - William H Stimson
- Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK
| | - Alexander B Mullen
- Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK
| | - Valerie A Ferro
- Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK.
| |
Collapse
|
17
|
Spears BR, Waksal J, McQuade C, Lanier L, Harth E. Controlled branching of polyglycidol and formation of protein-glycidol bioconjugates via a graft-from approach with "PEG-like" arms. Chem Commun (Camb) 2013; 49:2394-6. [PMID: 23370543 DOI: 10.1039/c3cc38369e] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The control of the branching in polyglycidols as semibranched alternatives to traditional polyglycidols is presented. The relative abundance of dendritic carbons is lowered by five-fold compared to hyperbranched polyglycidols. It is the first example of tailoring the branching in polyglycidol and creating protein-glycidol bioconjugates as alternatives to pegylated biostructures.
Collapse
Affiliation(s)
- Benjamin R Spears
- Vanderbilt University, Department of Chemistry, 7619 Stevenson Center, Nashville, Tennessee, USA
| | | | | | | | | |
Collapse
|
18
|
Mittal A, Raber AS, Lehr CM, Hansen S. Particle based vaccine formulations for transcutaneous immunization. Hum Vaccin Immunother 2013; 9:1950-5. [PMID: 23778884 DOI: 10.4161/hv.25217] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Vaccine formulations on the basis of nano- (NP) or microparticles (MP) can solve issues with stabilization, controlled release, and poor immunogenicity of antigens. Likewise transcutaneous immunization (TCI) promises superior immunogenicity as well as the advantages of needle-free application compared with conventional intramuscular injections. Thus the combination of both strategies seems to be a very valuable approach. However, until now TCI using particle based vaccine formulations has made no impact on medical practice. One of the main difficulties is that NPs and MPs cannot penetrate the skin to an extent that would allow the application of the required dose of antigen. This is due to the formidable stratum corneum (SC) barrier, the limited amount of antigen in the formulation and often an insufficient immunogenicity. A multitude of strategies are currently under investigation to overcome these issues. We highlight selected methods presenting a spectrum of solutions ranging from transfollicular delivery, to devices disrupting the SC barrier and the combination of particle based vaccines with adjuvants discussing their advantages and shortcomings. Some of these are currently at an experimental state while others are already in clinical testing. All methods have been shown to be capable of transcutaneous antigen delivery.
Collapse
Affiliation(s)
- Ankit Mittal
- Biopharmaceutics and Pharmaceutical Technology; Saarland University; Saarbruecken, Germany
| | | | | | | |
Collapse
|
19
|
Guastella AJ, Hickie IB, McGuinness MM, Otis M, Woods EA, Disinger HM, Chan HK, Chen TF, Banati RB. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 2013; 38:612-25. [PMID: 23265311 DOI: 10.1016/j.psyneuen.2012.11.019] [Citation(s) in RCA: 272] [Impact Index Per Article: 24.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2012] [Revised: 11/25/2012] [Accepted: 11/26/2012] [Indexed: 12/20/2022]
Abstract
A series of studies have reported on the salubrious effects of oxytocin nasal spray on social cognition and behavior in humans, across physiology (e.g., eye gaze, heart rate variability), social cognition (e.g., attention, memory, and appraisal), and behavior (e.g., trust, generosity). Findings suggest the potential of oxytocin nasal spray as a treatment for various psychopathologies, including autism and schizophrenia. There are, however, increasing reports of variability of response to oxytocin nasal spray between experiments and individuals. In this review, we provide a summary of factors that influence transmucosal nasal drug delivery, deposition, and their impact on bioavailability. These include variations in anatomy and resultant airflow dynamic, vascularisation, status of blood vessels, mode of spray application, gallenic formulation (including presence of uptake enhancers, control release formulation), and amount and method of administration. These key variables are generally poorly described and controlled in scientific reports, in spite of their potential to alter the course of treatment outcome studies. Based on this review, it should be of no surprise that differences emerge across individuals and experiments when nasal drug delivery methods are employed. We present recommendations for researchers to use when developing and administering the spray, and guidelines for reporting on peptide nasal spray studies in humans. We hope that these recommendations assist in establishing a scientific standard that can improve the rigor and subsequent reliability of reported effects of oxytocin nasal spray in humans.
Collapse
Affiliation(s)
- Adam J Guastella
- Brain & Mind Research Institute, University of Sydney, Sydney 2006, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Wang HW, Jiang PL, Lin SF, Lin HJ, Ou KL, Deng WP, Lee LW, Huang YY, Liang PH, Liu DZ. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. Acta Biomater 2013; 9:5681-8. [PMID: 23159567 DOI: 10.1016/j.actbio.2012.11.007] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2012] [Revised: 10/01/2012] [Accepted: 11/06/2012] [Indexed: 01/01/2023]
Abstract
The mucosal immune system produces secretory IgA (sIgA) as the first line of defense against invasion by foreign pathogens. Our aim was to develop a galactose-modified liposome as a targeted carrier which can be specifically recognized by macrophage, one of the most important antigen presenting cells. First, galactose was covalently conjugated with 1,2-didodecanoyl-sn-glycero-3-phosphoethanolamine (DLPE) to give a targeted ligand, a galactosyl lipid. The galactosyl lipid was then incorporated into a liposomal bilayer to form a galactosylated liposome carrier. Further, the ovalbumin (OVA) was encapsulated into the galactosylated liposome carriers and mice were intranasally immunized. Confocal laser scanning microscopy and flow cytometry analysis showed that the targeted galactosylated liposome carrier had a higher uptake rate than unmodified liposomes. The targeted galactosylated liposome induced higher levels of tumor necrosis factor-α and interleukin-6 production than unmodified liposomes (P<0.05). Furthermore, 6-week-old BALB/c female mice immunized with the OVA-encapsulated targeted galactosylated liposome had significantly higher OVA-specific s-IgA levels in the nasal and lung wash fluid (P<0.05). In addition, the targeted galactosylated liposome simultaneously augmented the serum IgG antibody response. In summary, the OVA-encapsulated targeted galactosylated liposome induced significantly higher mucosal IgA and systemic IgG antibody titers and is a potential antigen delivery carrier for further clinical applications.
Collapse
Affiliation(s)
- Hsiao-Wen Wang
- School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier. ScientificWorldJournal 2013; 2013:903234. [PMID: 23431260 PMCID: PMC3575622 DOI: 10.1155/2013/903234] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Accepted: 12/30/2012] [Indexed: 12/13/2022] Open
Abstract
The usefulness of pH-sensitive fusogenic polymer-(succinylated poly(glycidol)-(SucPG-) modified liposomes as a vaccine carrier in the induction of immune responses was evaluated. Mice were intraperitoneally immunized with ovalbumin- (OVA-) containing SucPG-modified liposomes. After immunization, significant OVA-specific antibodies were detected in the serum. When sera were analyzed for isotype distribution, OVA-specific IgG1 antibody responses were noted in mice immunized with OVA-containing polymer-unmodified liposomes, whereas immunization with OVA-containing SucPG-modified liposomes resulted in the induction of OVA-specific IgG1, IgG2a, and IgG3 Ab responses. In spleen lymphocytes from mice immunized with OVA-containing SucPG-modified liposomes, both IFN-γ-(Th1-type-) and IL-4-(Th2 type-) specific mRNA were detected. Moreover, substantial production of IFN-γ and IL-4 was demonstrated in spleen cells from OVA-containing SucPG-modified liposomes in vitro. These results suggest that the pH-sensitive fusogenic polymer-(SucPG-) modified liposomes would serve effectively as an antigen delivery vehicle for inducing Th1 and Th2 immune responses.
Collapse
|
22
|
Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine (Lond) 2012; 7:1877-93. [DOI: 10.2217/nnm.12.157] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The discovery of liposomes in 1965 by Bangham and coworkers changed the prospects of drug delivery systems. Since then, the application of liposomes as vaccine delivery systems has been studied extensively. Liposomal vaccine delivery systems are made up of nano- or micro-sized vesicles consisting of phospholipid bilayers, in which the bioactive molecule is encapsulated/entrapped, adsorbed or surface coupled. In general, liposomes are not immunogenic on their own; thus, liposomes combined with immunostimulating ligands (adjuvants) or various other formulations have been used as vaccine delivery systems. A thorough understanding of formulation parameters allows the design of effective liposomal vaccine delivery systems. This article provides an overview of various factors that influence liposomal immunogenicity. In particular, the effects of vesicle size, surface charge, bilayer composition, lamellarity, pegylation and targeting of liposomes are described.
Collapse
Affiliation(s)
- Ashwini Kumar Giddam
- The University of Queensland, School of Chemistry & Molecular Biosciences, St Lucia, QLD 4072, Australia
| | - Mehfuz Zaman
- The University of Queensland, School of Chemistry & Molecular Biosciences, St Lucia, QLD 4072, Australia
| | - Mariusz Skwarczynski
- The University of Queensland, School of Chemistry & Molecular Biosciences, St Lucia, QLD 4072, Australia
| | - Istvan Toth
- The University of Queensland, School of Pharmacy, St Lucia, QLD 4072, Australia
| |
Collapse
|
23
|
Higa LH, Schilrreff P, Perez AP, Iriarte MA, Roncaglia DI, Morilla MJ, Romero EL. Ultradeformable archaeosomes as new topical adjuvants. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2012; 8:1319-28. [DOI: 10.1016/j.nano.2012.02.008] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/15/2011] [Revised: 01/22/2012] [Accepted: 02/13/2012] [Indexed: 11/30/2022]
|
24
|
Dionísio M, Grenha A. Locust bean gum: Exploring its potential for biopharmaceutical applications. J Pharm Bioallied Sci 2012; 4:175-85. [PMID: 22923958 PMCID: PMC3425165 DOI: 10.4103/0975-7406.99013] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2012] [Revised: 03/21/2012] [Accepted: 04/24/2012] [Indexed: 12/21/2022] Open
Abstract
Polysaccharides have been finding, in the last decades, very interesting and useful applications in the biomedical and, specifically, in the biopharmaceutical field. Locust bean gum is a polysaccharide belonging to the group of galactomannans, being extracted from the seeds of the carob tree (Ceratonia siliqua). This polymer displays a number of appealing characteristics for biopharmaceutical applications, among which its high gelling capacity should be highlighted. In this review, we describe critical aspects of locust bean gum, contributing for its role in biopharmaceutical applications. Physicochemical properties, as well as strong and effective synergies with other biomaterials are described. The potential for in vivo biodegradation is explored and the specific biopharmaceutical applications are discussed.
Collapse
Affiliation(s)
- Marita Dionísio
- CBME - Centre for Molecular and Structural Biomedicine/IBB - Institute for Biotechnology and Bioengineering, Faculty of Sciences and Technology, University of Algarve, Campus de Gambelas, Faro, Portugal
| | | |
Collapse
|
25
|
Abstract
Mucosal surfaces are a major portal of entry for many human pathogens that are the cause of infectious diseases worldwide. Vaccines capable of eliciting mucosal immune responses can fortify defenses at mucosal front lines and protect against infection. However, most licensed vaccines are administered parenterally and fail to elicit protective mucosal immunity. Immunization by mucosal routes may be more effective at inducing protective immunity against mucosal pathogens at their sites of entry. Recent advances in our understanding of mucosal immunity and identification of correlates of protective immunity against specific mucosal pathogens have renewed interest in the development of mucosal vaccines. Efforts have focused on efficient delivery of vaccine antigens to mucosal sites that facilitate uptake by local antigen-presenting cells to generate protective mucosal immune responses. Discovery of safe and effective mucosal adjuvants are also being sought to enhance the magnitude and quality of the protective immune response.
Collapse
Affiliation(s)
- Kim A Woodrow
- Department of Bioengineering, University of Washington, Seattle, Washington 98195, USA.
| | | | | |
Collapse
|
26
|
Popov M, Grinberg S, Linder C, Waner T, Levi-Hevroni B, Deckelbaum RJ, Heldman E. Site-directed decapsulation of bolaamphiphilic vesicles with enzymatic cleavable surface groups. J Control Release 2011; 160:306-14. [PMID: 22226780 DOI: 10.1016/j.jconrel.2011.12.022] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2011] [Revised: 12/16/2011] [Accepted: 12/17/2011] [Indexed: 12/20/2022]
Abstract
Stable nano-sized vesicles with a monolayer encapsulating membrane were prepared from novel bolaamphiphiles with choline ester head groups. The head groups were covalently bound to the alkyl chain of the bolaamphiphiles either via the nitrogen atom of the choline moiety, or via the choline ester's methyl group. Both types of bolaamphiphiles competed with acetylthiocholine for binding to acetylcholine esterase (AChE), yet, only the choline ester head groups bound to the alkyl chain via the nitrogen atom of the choline moiety were hydrolyzed by the enzyme. Likewise, only vesicles composed of bolaamphiphiles with head groups that were hydrolyzed by AChE released their encapsulated material upon exposure to the enzyme. Injection of carboxyfluorescein (CF)-loaded vesicles with cleavable choline ester head groups into mice resulted in the accumulation of CF in tissues that express high AChE activity, including the brain. By comparison, when vesicles with choline ester head groups that are not hydrolyzed by AChE were injected into mice, there was no accumulation of CF in tissues that highly express the enzyme. These results imply that bolaamphiphilic vesicles with surface groups that are substrates to enzymes which are highly expressed in target organs may potentially be used as a drug delivery system with controlled site-directed drug release.
Collapse
Affiliation(s)
- Mary Popov
- Department of Clinical Biochemistry, Ben-Gurion University of the Negev, Beer Sheva, Israel.
| | | | | | | | | | | | | |
Collapse
|
27
|
Li X, Chen D, Le C, Zhu C, Gan Y, Hovgaard L, Yang M. Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake. Int J Nanomedicine 2011; 6:3151-62. [PMID: 22163166 PMCID: PMC3235033 DOI: 10.2147/ijn.s25741] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Background The aim of this study was to investigate the intestinal mucus-penetrating properties and intestinal cellular uptake of two types of liposomes modified by Pluronic F127 (PF127). Methods The two types of liposomes, ie, PF127-inlaid liposomes and PF127-adsorbed liposomes, were prepared by a thin-film hydration method followed by extrusion, in which coumarin 6 was loaded as a fluorescence marker. A modified Franz diffusion cell mounted with the intestinal mucus of rats was used to study the diffusion characteristics of the two types of PF127 liposomes. Cell uptake studies were conducted in Caco-2 cells and analyzed using confocal laser scanning microcopy as well as flow cytometry. Results The diffusion efficiency of the two types of PF127-modified liposomes through intestinal rat mucus was 5–7-fold higher than that of unmodified liposomes. Compared with unmodified liposomes, PF127-inlaid liposomes showed significantly higher cellular uptake of courmarin 6. PF127-adsorbed liposomes showed a lower cellular uptake. Moreover, and interestingly, the two types of PF127-modified liposomes showed different cellular uptake mechanisms in Caco-2 cells. Conclusion PF127-inlaid liposomes with improved intestinal mucus-penetrating ability and enhanced cellular uptake might be a potential carrier candidate for oral drug delivery.
Collapse
Affiliation(s)
- Xiuying Li
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | | | | | | | | | | | | |
Collapse
|
28
|
BiotecVisions 2011, October. Biotechnol J 2011. [DOI: 10.1002/biot.201100428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
29
|
Abstract
The living epidermis and dermis are rich in antigen presenting cells (APCs). Their activation can elicit a strong humoral and cellular immune response as well as mucosal immunity. Therefore, the skin is a very attractive site for vaccination, and an intradermal application of antigen may be much more effective than a subcutaneous or intramuscular injection. However, the stratum corneum (SC) is a most effective barrier against the invasion of topically applied vaccines. Products which have reached the stage of clinical testing, avoid this problem by injecting the nano‐vaccine intradermally or by employing a barrier disrupting method and applying the vaccine to a relatively large skin area. Needle‐free vaccination is desirable from a number of aspects: ease of application, improved patient acceptance and less risk of infection among them. Nanocarriers can be designed in a way that they can overcome the SC. Also incorporation into nanocarriers protects instable antigen from degradation, improves uptake and processing by APCs, and facilitates endosomal escape and nuclear delivery of DNA vaccines. In addition, sustained release systems may build a depot in the tissue gradually releasing antigen which may avoid booster doses. Therefore, nanoformulations of vaccines for transcutaneous immunization are currently a very dynamic field of research. Among the huge variety of nanocarrier systems that are investigated hopes lie on ultra‐flexible liposomes, superfine rigid nanoparticles and nanocarriers, which are taken up by hair follicles. The potential and pitfalls associated with these three classes of carriers will be discussed.
Collapse
Affiliation(s)
- Steffi Hansen
- Department of Drug Delivery, Helmholtz-Institute for Pharmaceutical Research Saarland-HIPS, Helmholtz-Center for Infection Research-HZI, Saarbruecken, Germany.
| | | |
Collapse
|